[PDF][PDF] Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma

Y Yu, K Schleich, B Yue, S Ji, P Lohneis, K Kemper… - Cancer cell, 2018 - cell.com
Y Yu, K Schleich, B Yue, S Ji, P Lohneis, K Kemper, MR Silvis, N Qutob, E van Rooijen
Cancer cell, 2018cell.com
Oncogene-induced senescence, eg, in melanocytic nevi, terminates the expansion of pre-
malignant cells via transcriptional silencing of proliferation-related genes due to decoration
of their promoters with repressive trimethylated histone H3 lysine 9 (H3K9) marks. We show
here that structurally distinct H3K9-active demethylases—the lysine-specific demethylase-1
(LSD1) and several Jumonji C domain-containing moieties (such as JMJD2C)—disable
senescence and permit Ras/Braf-evoked transformation. In mouse and zebrafish models …
Summary
Oncogene-induced senescence, e.g., in melanocytic nevi, terminates the expansion of pre-malignant cells via transcriptional silencing of proliferation-related genes due to decoration of their promoters with repressive trimethylated histone H3 lysine 9 (H3K9) marks. We show here that structurally distinct H3K9-active demethylases—the lysine-specific demethylase-1 (LSD1) and several Jumonji C domain-containing moieties (such as JMJD2C)—disable senescence and permit Ras/Braf-evoked transformation. In mouse and zebrafish models, enforced LSD1 or JMJD2C expression promoted Braf-V600E-driven melanomagenesis. A large subset of established melanoma cell lines and primary human melanoma samples presented with a collective upregulation of related and unrelated H3K9 demethylase activities, whose targeted inhibition restored senescence, even in Braf inhibitor-resistant melanomas, evoked secondary immune effects and controlled tumor growth in vivo.
cell.com